메뉴 건너뛰기




Volumn 11, Issue 11, 2012, Pages 873-886

Vemurafenib: The first drug approved for BRAF-mutant cancer

Author keywords

[No Author keywords available]

Indexed keywords

B RAF KINASE; B RAF KINASE INHIBITOR; N [3 (5 CHLORO 1H PYRROLO[2,3 B]PYRIDINE 3 CARBONYL) 2,4 DIFLUOROPHENYL]PROPANESULFONAMIDE; VEMURAFENIB;

EID: 84868481873     PISSN: 14741776     EISSN: 14741784     Source Type: Journal    
DOI: 10.1038/nrd3847     Document Type: Review
Times cited : (680)

References (138)
  • 2
    • 0021341930 scopus 로고
    • The human homologs of the raf(mil) oncogene are located on human chromosomes 3 and 4
    • Bonner, T. et al. The human homologs of the raf (mil) oncogene are located on human chromosomes 3 and 4. Science 223, 71-74 (1984). (Pubitemid 14209914)
    • (1984) Science , vol.223 , Issue.4631 , pp. 71-74
    • Bonner, T.1    O'Brien, S.J.2    Nash, W.G.3
  • 3
    • 0021711728 scopus 로고
    • Serine- and threonine-specific protein kinase activities of purified gag-mil and gag-raf proteins
    • DOI 10.1038/312558a0
    • Moelling, K., Heimann, B., Beimling, P., Rapp, U. R. & Sander, T. Serine-and threonine-specific protein kinase activities of purified gag-mil and gag-raf proteins. Nature 312, 558-561 (1984). (Pubitemid 15182287)
    • (1984) Nature , vol.312 , Issue.5994 , pp. 558-561
    • Moelling, K.1    Heimann, B.2    Beimling, P.3
  • 4
    • 0022755881 scopus 로고
    • Characterization of murine A-raf, a new oncogene related to the v-raf oncogene
    • Huleihel, M. et al. Characterization of murine A-raf, a new oncogene related to the v-raf oncogene. Mol. Cell. Biol. 6, 2655-2662 (1986).
    • (1986) Mol. Cell. Biol , vol.6 , pp. 2655-2662
    • Huleihel, M.1
  • 5
    • 0023133794 scopus 로고
    • The complete coding sequence of the human A-raf-1 oncogene and transforming activity of a human A-raf carrying retrovirus
    • Beck, T. W., Huleihel, M., Gunnell, M., Bonner, T. I. & Rapp, U. R. The complete coding sequence of the human A-raf-1 oncogene and transforming activity of a human A-raf carrying retrovirus. Nucleic Acids Res. 15, 595-609 (1987). (Pubitemid 17233996)
    • (1987) Nucleic Acids Research , vol.15 , Issue.2 , pp. 595-609
    • Beck, T.W.1    Huleihel, M.2    Gunnell, M.3
  • 6
    • 0024026952 scopus 로고
    • B-raf, a new member of the raf family, is activated by DNA rearrangement
    • Ikawa, S. et al. B-raf, a new member of the raf family, is activated by DNA rearrangement. Mol. Cell. Biol. 8, 2651-2654 (1988).
    • (1988) Mol. Cell. Biol , vol.8 , pp. 2651-2654
    • Ikawa, S.1
  • 7
    • 0024119653 scopus 로고
    • A novel oncogene related to c-mil is transduced in chicken neuroretina cells induced to proliferate by infection with an avian lymphomatosis virus
    • Marx, M. et al. A novel oncogene related to c-mil is transduced in chicken neuroretina cells induced to proliferate by infection with an avian lymphomatosis virus. EMBO J. 7, 3369-3373 (1988).
    • (1988) EMBO J , vol.7 , pp. 3369-3373
    • Marx, M.1
  • 9
    • 0036654443 scopus 로고    scopus 로고
    • A genome-based strategy uncovers frequent BRAF mutations in melanoma
    • DOI 10.1016/S1535-6108(02)00089-2
    • Pollock, P. M. & Meltzer, P. S. A genome-based strategy uncovers frequent BRAF mutations in melanoma. Cancer Cell 2, 5-7 (2002). (Pubitemid 41043982)
    • (2002) Cancer Cell , vol.2 , Issue.1 , pp. 5-7
    • Pollock, P.M.1    Meltzer, P.S.2
  • 13
    • 0037379904 scopus 로고    scopus 로고
    • High prevalence of BRAF mutations in thyroid cancer: Genetic evidence for constitutive activation of the RET/PTC-RAS-BRAF signaling pathway in papillary thyroid carcinoma
    • Kimura, E. T. et al. High prevalence of BRAF mutations in thyroid cancer: genetic evidence for constitutive activation of the RET/PTC-RAS-BRAF signaling pathway in papillary thyroid carcinoma. Cancer Res. 63, 1454-1457 (2003). (Pubitemid 36373628)
    • (2003) Cancer Research , vol.63 , Issue.7 , pp. 1454-1457
    • Kimura, E.T.1    Nikiforova, M.N.2    Zhu, Z.3    Knauf, J.A.4    Nikiforov, Y.E.5    Fagin, J.A.6
  • 14
    • 0041589377 scopus 로고    scopus 로고
    • High prevalence of BRAF gene mutation in papillary thyroid carcinomas and thyroid tumor cell lines
    • Xu, X., Quiros, R. M., Gattuso, P., Ain, K. B. & Prinz, R. A. High prevalence of BRAF gene mutation in papillary thyroid carcinomas and thyroid tumor cell lines. Cancer Res. 63, 4561-4567 (2003). (Pubitemid 36951030)
    • (2003) Cancer Research , vol.63 , Issue.15 , pp. 4561-4567
    • Xu, X.1    Quiros, R.M.2    Gattuso, P.3    Ain, K.B.4    Prinz, R.A.5
  • 22
    • 84856845687 scopus 로고    scopus 로고
    • BRAF and PIK3CA genes are somatically mutated in hepatocellular carcinoma among patients from South Italy
    • Colombino, M. et al. BRAF and PIK3CA genes are somatically mutated in hepatocellular carcinoma among patients from South Italy. Cell Death Dis. 3, e259 (2012).
    • (2012) Cell Death Dis , vol.3
    • Colombino, M.1
  • 23
    • 77956904045 scopus 로고    scopus 로고
    • Recurrent BRAF mutations in Langerhans cell histiocytosis
    • Badalian-Very, G. et al. Recurrent BRAF mutations in Langerhans cell histiocytosis. Blood 116, 1919-1923 (2010).
    • (2010) Blood , vol.116 , pp. 1919-1923
    • Badalian-Very, G.1
  • 24
    • 50249152932 scopus 로고    scopus 로고
    • Novel V600E BRAF mutations in imatinib-naive and imatinib-resistant gastrointestinal stromal tumors
    • Agaram, N. P. et al. Novel V600E BRAF mutations in imatinib-naive and imatinib-resistant gastrointestinal stromal tumors. Genes Chromosomes Cancer 47, 853-859 (2008).
    • (2008) Genes Chromosomes Cancer , vol.47 , pp. 853-859
    • Agaram, N.P.1
  • 25
    • 79951494668 scopus 로고    scopus 로고
    • Initial genome sequencing and analysis of multiple myeloma
    • Chapman, M. A. et al. Initial genome sequencing and analysis of multiple myeloma. Nature 471, 467-472 (2011).
    • (2011) Nature , vol.471 , pp. 467-472
    • Chapman, M.A.1
  • 26
    • 55349107544 scopus 로고    scopus 로고
    • Tandem duplication producing a novel oncogenic BRAF fusion gene defines the majority of pilocytic astrocytomas
    • Jones, D. T. et al. Tandem duplication producing a novel oncogenic BRAF fusion gene defines the majority of pilocytic astrocytomas. Cancer Res. 68, 8673-8677 (2008).
    • (2008) Cancer Res , vol.68 , pp. 8673-8677
    • Jones, D.T.1
  • 28
    • 66949147222 scopus 로고    scopus 로고
    • Duplication of 7q34 in pediatric low-grade astrocytomas detected by high-density single-nucleotide polymorphism-based genotype arrays results in a novel BRAF fusion gene
    • Sievert, A. J. et al. Duplication of 7q34 in pediatric low-grade astrocytomas detected by high-density single-nucleotide polymorphism-based genotype arrays results in a novel BRAF fusion gene. Brain Pathol. 19, 449-458 (2009).
    • (2009) Brain Pathol , vol.19 , pp. 449-458
    • Sievert, A.J.1
  • 29
    • 79953184268 scopus 로고    scopus 로고
    • BRAF V600E mutations are common in pleomorphic xanthoastrocytoma: Diagnostic and therapeutic implications
    • Dias-Santagata, D. et al. BRAF V600E mutations are common in pleomorphic xanthoastrocytoma: diagnostic and therapeutic implications. PLoS ONE 6, e17948 (2011).
    • (2011) PLoS ONE , vol.6
    • Dias-Santagata, D.1
  • 30
    • 79954441895 scopus 로고    scopus 로고
    • Analysis of BRAF V600E mutation in 1,320 nervous system tumors reveals high mutation frequencies in pleomorphic xanthoastrocytoma, ganglioglioma and extra-cerebellar pilocytic astrocytoma
    • Schindler, G. et al. Analysis of BRAF V600E mutation in 1,320 nervous system tumors reveals high mutation frequencies in pleomorphic xanthoastrocytoma, ganglioglioma and extra-cerebellar pilocytic astrocytoma. Acta Neuropathol. 121, 397-405 (2011).
    • (2011) Acta Neuropathol , vol.121 , pp. 397-405
    • Schindler, G.1
  • 31
    • 79959293462 scopus 로고    scopus 로고
    • BRAF mutations in hairy-cell leukemia
    • Tiacci, E. et al. BRAF mutations in hairy-cell leukemia. N. Engl. J. Med. 364, 2305-2315 (2011).
    • (2011) N. Engl. J. Med , vol.364 , pp. 2305-2315
    • Tiacci, E.1
  • 35
    • 0042885906 scopus 로고    scopus 로고
    • BRAF as a potential therapeutic target in melanoma and other malignancies
    • DOI 10.1016/S1535-6108(03)00189-2
    • Tuveson, D. A., Weber, B. L. & Herlyn, M. BRAF as a potential therapeutic target in melanoma and other malignancies. Cancer Cell 4, 95-98 (2003). (Pubitemid 37040825)
    • (2003) Cancer Cell , vol.4 , Issue.2 , pp. 95-98
    • Tuveson, D.A.1    Weber, B.L.2    Herlyn, M.3
  • 37
    • 1942506706 scopus 로고    scopus 로고
    • V599EB-RAF is an oncogene in melanocytes
    • Wellbrock, C. et al. V599EB-RAF is an oncogene in melanocytes. Cancer Res. 64, 2338-2342 (2004).
    • (2004) Cancer Res , vol.64 , pp. 2338-2342
    • Wellbrock, C.1
  • 40
    • 33847201454 scopus 로고    scopus 로고
    • A new mouse model to explore the initiation, progression, and therapy of BRAFV600E-induced lung tumors
    • Dankort, D. et al. A new mouse model to explore the initiation, progression, and therapy of BRAFV600E-induced lung tumors. Genes Dev. 21, 379-384 (2007).
    • (2007) Genes Dev , vol.21 , pp. 379-384
    • Dankort, D.1
  • 41
    • 58049220349 scopus 로고    scopus 로고
    • BRAF activation initiates but does not maintain invasive prostate adenocarcinoma
    • Jeong, J. H. et al. BRAF activation initiates but does not maintain invasive prostate adenocarcinoma. PLoS ONE 3, e3949 (2008).
    • (2008) PLoS ONE , vol.3
    • Jeong, J.H.1
  • 42
    • 65649147543 scopus 로고    scopus 로고
    • BrafV600E cooperates with Pten loss to induce metastatic melanoma
    • Dankort, D. et al. BrafV600E cooperates with Pten loss to induce metastatic melanoma. Nature Genet. 41, 544-552 (2009).
    • (2009) Nature Genet , vol.41 , pp. 544-552
    • Dankort, D.1
  • 43
    • 67349212438 scopus 로고    scopus 로고
    • Melanocytic nevus-like hyperplasia and melanoma in transgenic BRAFV600E mice
    • Goel, V. K. et al. Melanocytic nevus-like hyperplasia and melanoma in transgenic BRAFV600E mice. Oncogene 28, 2289-2298 (2009).
    • (2009) Oncogene , vol.28 , pp. 2289-2298
    • Goel, V.K.1
  • 44
    • 84055191090 scopus 로고    scopus 로고
    • Small-molecule MAPK inhibitors restore radioiodine incorporation in mouse thyroid cancers with conditional BRAF activation
    • Chakravarty, D. et al. Small-molecule MAPK inhibitors restore radioiodine incorporation in mouse thyroid cancers with conditional BRAF activation. J. Clin. Invest. 121, 4700-4711 (2011).
    • (2011) J. Clin. Invest , vol.121 , pp. 4700-4711
    • Chakravarty, D.1
  • 45
    • 79957909599 scopus 로고    scopus 로고
    • Mutationally activated BRAFV600E elicits papillary thyroid cancer in the adult mouse
    • Charles, R. P., Iezza, G., Amendola, E., Dankort, D. & McMahon, M. Mutationally activated BRAFV600E elicits papillary thyroid cancer in the adult mouse. Cancer Res. 71, 3863-3871 (2011).
    • (2011) Cancer Res , vol.71 , pp. 3863-3871
    • Charles, R.P.1    Iezza, G.2    Amendola, E.3    Dankort, D.4    McMahon, M.5
  • 49
    • 61449175950 scopus 로고    scopus 로고
    • Sorafenib for the treatment of unresectable hepatocellular carcinoma
    • Kane, R. C. et al. Sorafenib for the treatment of unresectable hepatocellular carcinoma. Oncologist 14, 95-100 (2009).
    • (2009) Oncologist , vol.14 , pp. 95-100
    • Kane, R.C.1
  • 51
    • 51049095131 scopus 로고    scopus 로고
    • A phase i trial of the oral, multikinase inhibitor sorafenib in combination with carboplatin and paclitaxel
    • Flaherty, K. T. et al. A phase I trial of the oral, multikinase inhibitor sorafenib in combination with carboplatin and paclitaxel. Clin. Cancer Res. 14, 4836-4842 (2008).
    • (2008) Clin. Cancer Res , vol.14 , pp. 4836-4842
    • Flaherty, K.T.1
  • 52
    • 67649909568 scopus 로고    scopus 로고
    • Results of a phase III, randomized, placebo-controlled study of sorafenib in combination with carboplatin and paclitaxel as second-line treatment in patients with unresectable stage III or stage IV melanoma
    • Hauschild, A. et al. Results of a phase III, randomized, placebo-controlled study of sorafenib in combination with carboplatin and paclitaxel as second-line treatment in patients with unresectable stage III or stage IV melanoma. J. Clin. Oncol. 27, 2823-2830 (2009).
    • (2009) J. Clin. Oncol , vol.27 , pp. 2823-2830
    • Hauschild, A.1
  • 53
    • 78650824497 scopus 로고    scopus 로고
    • A phase II trial of sorafenib in metastatic melanoma with tissue correlates
    • Ott, P. A. et al. A phase II trial of sorafenib in metastatic melanoma with tissue correlates. PLoS ONE 5, e15588 (2010).
    • (2010) PLoS ONE , vol.5
    • Ott, P.A.1
  • 55
    • 84868193136 scopus 로고    scopus 로고
    • Cutaneous manifestations of dabrafenib (GSK2118436): A selective inhibitor of mutant BRAF in patients with metastatic melanoma
    • 16 Jul doi:10.1111/j.1365-2133.2012.11155.x
    • Anforth, R. M. et al. Cutaneous manifestations of dabrafenib (GSK2118436): a selective inhibitor of mutant BRAF in patients with metastatic melanoma. Br. J. Dermatol. 16 Jul 2012 (doi:10.1111/j.1365-2133.2012.11155.x).
    • (2012) Br. J. Dermatol.
    • Anforth, R.M.1
  • 56
    • 84861083983 scopus 로고    scopus 로고
    • Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: A phase 1 dose-escalation trial
    • Falchook, G. S. et al. Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial. Lancet 379, 1893-1901 (2012).
    • (2012) Lancet , vol.379 , pp. 1893-1901
    • Falchook, G.S.1
  • 57
    • 84864285704 scopus 로고    scopus 로고
    • Dabrafenib in BRAF-mutated metastatic melanoma: A multicentre, open-label, phase 3 randomised controlled trial
    • Hauschild, A. et al. Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial. Lancet 380, 358-365 (2012).
    • (2012) Lancet , vol.380 , pp. 358-365
    • Hauschild, A.1
  • 58
    • 84859873585 scopus 로고    scopus 로고
    • RAF265 inhibits the growth of advanced human melanoma tumors
    • Su, Y. et al. RAF265 inhibits the growth of advanced human melanoma tumors. Clin. Cancer Res. 18, 2184-2198 (2012).
    • (2012) Clin. Cancer Res , vol.18 , pp. 2184-2198
    • Su, Y.1
  • 59
    • 84862735870 scopus 로고    scopus 로고
    • CEP-32496: A novel orally active BRAF(V600E) inhibitor with selective cellular and in vivo antitumor activity
    • James, J. et al. CEP-32496: a novel orally active BRAF(V600E) inhibitor with selective cellular and in vivo antitumor activity. Mol. Cancer Ther. 11, 930-941 (2012).
    • (2012) Mol. Cancer Ther , vol.11 , pp. 930-941
    • James, J.1
  • 60
    • 57749188299 scopus 로고    scopus 로고
    • Targeting cancer with small molecule kinase inhibitors
    • Zhang, J., Yang, P. L. & Gray, N. S. Targeting cancer with small molecule kinase inhibitors. Nature Rev. Cancer 9, 28-39 (2009).
    • (2009) Nature Rev. Cancer , vol.9 , pp. 28-39
    • Zhang, J.1    Yang, P.L.2    Gray, N.S.3
  • 63
    • 75849142553 scopus 로고    scopus 로고
    • Scaffold-based design of kinase inhibitors for cancer therapy
    • Zhang, C. & Bollag, G. Scaffold-based design of kinase inhibitors for cancer therapy. Curr. Opin. Genet. Dev. 20, 79-86 (2010).
    • (2010) Curr. Opin. Genet. Dev , vol.20 , pp. 79-86
    • Zhang, C.1    Bollag, G.2
  • 65
    • 67849113794 scopus 로고    scopus 로고
    • The rise of fragment-based drug discovery
    • Murray, C. W. & Rees, D. C. The rise of fragment-based drug discovery. Nature Chem. 1, 187-192 (2009).
    • (2009) Nature Chem , vol.1 , pp. 187-192
    • Murray, C.W.1    Rees, D.C.2
  • 66
    • 84860524795 scopus 로고    scopus 로고
    • Structural approaches to obtain kinase selectivity
    • Norman, R. A., Toader, D. & Ferguson, A. D. Structural approaches to obtain kinase selectivity. Trends Pharmacol. Sci. 33, 273-278 (2012).
    • (2012) Trends Pharmacol. Sci , vol.33 , pp. 273-278
    • Norman, R.A.1    Toader, D.2    Ferguson, A.D.3
  • 69
    • 58549087807 scopus 로고    scopus 로고
    • Scaffold-based discovery of indeglitazar, a PPAR pan-active anti-diabetic agent
    • Artis, D. R. et al. Scaffold-based discovery of indeglitazar, a PPAR pan-active anti-diabetic agent. Proc. Natl Acad. Sci. USA 106, 262-267 (2009).
    • (2009) Proc. Natl Acad. Sci. USA , vol.106 , pp. 262-267
    • Artis, D.R.1
  • 70
    • 77956513286 scopus 로고    scopus 로고
    • Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma
    • Bollag, G. et al. Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma. Nature 467, 596-599 (2010).
    • (2010) Nature , vol.467 , pp. 596-599
    • Bollag, G.1
  • 72
    • 77949354563 scopus 로고    scopus 로고
    • PLX4032, a selective BRAF(V600E) kinase inhibitor, activates the ERK pathway and enhances cell migration and proliferation of BRAF melanoma cells
    • Halaban, R. et al. PLX4032, a selective BRAF(V600E) kinase inhibitor, activates the ERK pathway and enhances cell migration and proliferation of BRAF melanoma cells. Pigment Cell Melanoma Res. 23, 190-200 (2010).
    • (2010) Pigment Cell Melanoma Res , vol.23 , pp. 190-200
    • Halaban, R.1
  • 73
    • 77957089182 scopus 로고    scopus 로고
    • The RAF inhibitor PLX4032 inhibits ERK signaling and tumor cell proliferation in a V600E BRAF-selective manner
    • Joseph, E. W. et al. The RAF inhibitor PLX4032 inhibits ERK signaling and tumor cell proliferation in a V600E BRAF-selective manner. Proc. Natl Acad. Sci. USA 107, 14903-14908 (2010).
    • (2010) Proc. Natl Acad. Sci. USA , vol.107 , pp. 14903-14908
    • Joseph, E.W.1
  • 74
    • 77957968556 scopus 로고    scopus 로고
    • PLX4032, a potent inhibitor of the B-Raf V600E oncogene, selectively inhibits V600E-positive melanomas
    • Lee, J. T. et al. PLX4032, a potent inhibitor of the B-Raf V600E oncogene, selectively inhibits V600E-positive melanomas. Pigment Cell Melanoma Res. 23, 820-827 (2010).
    • (2010) Pigment Cell Melanoma Res , vol.23 , pp. 820-827
    • Lee, J.T.1
  • 75
    • 77954235111 scopus 로고    scopus 로고
    • Targeting the mitogen-activated protein kinase pathway: Physiological feedback and drug response
    • Pratilas, C. A. & Solit, D. B. Targeting the mitogen-activated protein kinase pathway: physiological feedback and drug response. Clin. Cancer Res. 16, 3329-3334 (2010).
    • (2010) Clin. Cancer Res , vol.16 , pp. 3329-3334
    • Pratilas, C.A.1    Solit, D.B.2
  • 76
    • 77950954465 scopus 로고    scopus 로고
    • Differential sensitivity of melanoma cell lines with BRAFV600E mutation to the specific Raf inhibitor PLX4032
    • Sondergaard, J. N. et al. Differential sensitivity of melanoma cell lines with BRAFV600E mutation to the specific Raf inhibitor PLX4032. J. Transl. Med. 8, 39 (2010).
    • (2010) J. Transl. Med , vol.8 , pp. 39
    • Sondergaard, J.N.1
  • 77
    • 77956029013 scopus 로고    scopus 로고
    • Pharmacodynamic characterization of the efficacy signals due to selective BRAF inhibition with PLX4032 in malignant melanoma
    • Tap, W. D. et al. Pharmacodynamic characterization of the efficacy signals due to selective BRAF inhibition with PLX4032 in malignant melanoma. Neoplasia 12, 637-649 (2010).
    • (2010) Neoplasia , vol.12 , pp. 637-649
    • Tap, W.D.1
  • 78
    • 77954376912 scopus 로고    scopus 로고
    • RG7204 (PLX4032), a selective BRAFV600E inhibitor, displays potent antitumor activity in preclinical melanoma models
    • Yang, H. et al. RG7204 (PLX4032), a selective BRAFV600E inhibitor, displays potent antitumor activity in preclinical melanoma models. Cancer Res. 70, 5518-5527 (2010).
    • (2010) Cancer Res , vol.70 , pp. 5518-5527
    • Yang, H.1
  • 79
    • 47249097988 scopus 로고    scopus 로고
    • BRAF silencing by short hairpin RNA or chemical blockade by PLX4032 leads to different responses in melanoma and thyroid carcinoma cells
    • Sala, E. et al. BRAF silencing by short hairpin RNA or chemical blockade by PLX4032 leads to different responses in melanoma and thyroid carcinoma cells. Mol. Cancer Res. 6, 751-759 (2008).
    • (2008) Mol. Cancer Res , vol.6 , pp. 751-759
    • Sala, E.1
  • 80
    • 75149188152 scopus 로고    scopus 로고
    • Cytostatic activity of adenosine triphosphate-competitive kinase inhibitors in BRAF mutant thyroid carcinoma cells
    • Salerno, P. et al. Cytostatic activity of adenosine triphosphate- competitive kinase inhibitors in BRAF mutant thyroid carcinoma cells. J. Clin. Endocrinol. Metab. 95, 450-455 (2010).
    • (2010) J. Clin. Endocrinol. Metab , vol.95 , pp. 450-455
    • Salerno, P.1
  • 81
    • 77953276524 scopus 로고    scopus 로고
    • Recovery of phospho-ERK activity allows melanoma cells to escape from BRAF inhibitor therapy
    • Paraiso, K. H. et al. Recovery of phospho-ERK activity allows melanoma cells to escape from BRAF inhibitor therapy. Br. J. Cancer 102, 1724-1730 (2010).
    • (2010) Br. J. Cancer , vol.102 , pp. 1724-1730
    • Paraiso, K.H.1
  • 82
    • 77955757007 scopus 로고    scopus 로고
    • Akt3-mediated resistance to apoptosis in B-RAF-targeted melanoma cells
    • Shao, Y. & Aplin, A. E. Akt3-mediated resistance to apoptosis in B-RAF-targeted melanoma cells. Cancer Res. 70, 6670-6681 (2010).
    • (2010) Cancer Res , vol.70 , pp. 6670-6681
    • Shao, Y.1    Aplin, A.E.2
  • 83
    • 84861381332 scopus 로고    scopus 로고
    • Adaptive upregulation of FOXD3 and resistance to PLX4032/4720-induced cell death in mutant B-RAF melanoma cells
    • Basile, K. J., Abel, E. V. & Aplin, A. E. Adaptive upregulation of FOXD3 and resistance to PLX4032/4720-induced cell death in mutant B-RAF melanoma cells. Oncogene 31, 2471-2479 (2011).
    • (2011) Oncogene , vol.31 , pp. 2471-2479
    • Basile, K.J.1    Abel, E.V.2    Aplin, A.E.3
  • 84
    • 84862778070 scopus 로고    scopus 로고
    • Role and therapeutic potential of PI3K-mTOR signaling in de novo resistance to BRAF inhibition
    • Deng, W. et al. Role and therapeutic potential of PI3K-mTOR signaling in de novo resistance to BRAF inhibition. Pigment Cell Melanoma Res. 25, 248-258 (2012).
    • (2012) Pigment Cell Melanoma Res , vol.25 , pp. 248-258
    • Deng, W.1
  • 85
    • 78751648455 scopus 로고    scopus 로고
    • Hyperactivation of MEK-ERK1/2 signaling and resistance to apoptosis induced by the oncogenic B-RAF inhibitor, PLX4720, in mutant N-RAS melanoma cells
    • Kaplan, F. M., Shao, Y., Mayberry, M. M. & Aplin, A. E. Hyperactivation of MEK-ERK1/2 signaling and resistance to apoptosis induced by the oncogenic B-RAF inhibitor, PLX4720, in mutant N-RAS melanoma cells. Oncogene 30, 366-371 (2011).
    • (2011) Oncogene , vol.30 , pp. 366-371
    • Kaplan, F.M.1    Shao, Y.2    Mayberry, M.M.3    Aplin, A.E.4
  • 86
    • 84856217925 scopus 로고    scopus 로고
    • Concurrent loss of the PTEN and RB1 tumor suppressors attenuates RAF dependence in melanomas harboring V600EBRAF
    • Xing, F. et al. Concurrent loss of the PTEN and RB1 tumor suppressors attenuates RAF dependence in melanomas harboring V600EBRAF. Oncogene 31, 446-457 (2012).
    • (2012) Oncogene , vol.31 , pp. 446-457
    • Xing, F.1
  • 87
    • 29144462587 scopus 로고    scopus 로고
    • Wild-type and mutant B-RAF activate C-RAF through distinct mechanisms involving heterodimerization
    • DOI 10.1016/j.molcel.2005.10.022, PII S109727650501717X
    • Garnett, M. J., Rana, S., Paterson, H., Barford, D. & Marais, R. Wild-type and mutant B-RAF activate C-RAF through distinct mechanisms involving heterodimerization. Mol. Cell 20, 963-969 (2005). (Pubitemid 41814884)
    • (2005) Molecular Cell , vol.20 , Issue.6 , pp. 963-969
    • Garnett, M.J.1    Rana, S.2    Paterson, H.3    Barford, D.4    Marais, R.5
  • 88
    • 74849109743 scopus 로고    scopus 로고
    • Kinase-dead BRAF and oncogenic RAS cooperate to drive tumor progression through CRAF
    • Heidorn, S. J. et al. Kinase-dead BRAF and oncogenic RAS cooperate to drive tumor progression through CRAF. Cell 140, 209-221 (2010).
    • (2010) Cell , vol.140 , pp. 209-221
    • Heidorn, S.J.1
  • 89
    • 84863012433 scopus 로고    scopus 로고
    • Antitumor activity of BRAF inhibitor vemurafenib in preclinical models of BRAF-mutant colorectal cancer
    • Yang, H. et al. Antitumor activity of BRAF inhibitor vemurafenib in preclinical models of BRAF-mutant colorectal cancer. Cancer Res. 72, 779-789 (2012).
    • (2012) Cancer Res , vol.72 , pp. 779-789
    • Yang, H.1
  • 90
    • 70349438995 scopus 로고    scopus 로고
    • A dimerization-dependent mechanism drives RAF catalytic activation
    • Rajakulendran, T., Sahmi, M., Lefrancois, M., Sicheri, F. & Therrien, M. A dimerization-dependent mechanism drives RAF catalytic activation. Nature 461, 542-545 (2009).
    • (2009) Nature , vol.461 , pp. 542-545
    • Rajakulendran, T.1    Sahmi, M.2    Lefrancois, M.3    Sicheri, F.4    Therrien, M.5
  • 91
    • 77949732073 scopus 로고    scopus 로고
    • RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF
    • Poulikakos, P. I., Zhang, C., Bollag, G., Shokat, K. M. & Rosen, N. RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF. Nature 464, 427-430 (2010).
    • (2010) Nature , vol.464 , pp. 427-430
    • Poulikakos, P.I.1    Zhang, C.2    Bollag, G.3    Shokat, K.M.4    Rosen, N.5
  • 92
    • 77956030786 scopus 로고    scopus 로고
    • Inhibition of mutated, activated BRAF in metastatic melanoma
    • Flaherty, K. T. et al. Inhibition of mutated, activated BRAF in metastatic melanoma. N. Engl. J. Med. 363, 809-819 (2010).
    • (2010) N. Engl. J. Med , vol.363 , pp. 809-819
    • Flaherty, K.T.1
  • 93
    • 78649723255 scopus 로고    scopus 로고
    • PLX4032 in metastatic colorectal cancer patients with mutant BRAF tumors
    • Abstract 3534
    • Kopetz, S. et al. PLX4032 in metastatic colorectal cancer patients with mutant BRAF tumors. J. Clin. Oncol. 28, Abstract 3534 (2010).
    • (2010) J. Clin. Oncol. , vol.28
    • Kopetz, S.1
  • 94
    • 84863116743 scopus 로고    scopus 로고
    • Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib
    • Sosman, J. A. et al. Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib. N. Engl. J. Med. 366, 707-714 (2012).
    • (2012) N. Engl. J. Med , vol.366 , pp. 707-714
    • Sosman, J.A.1
  • 95
    • 79959795786 scopus 로고    scopus 로고
    • Improved survival with vemurafenib in melanoma with BRAF V600E mutation
    • Chapman, P. B. et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N. Engl. J. Med. 364, 2507-2516 (2011).
    • (2011) N. Engl. J. Med , vol.364 , pp. 2507-2516
    • Chapman, P.B.1
  • 96
    • 84863746052 scopus 로고    scopus 로고
    • Marked, homogeneous, and early [18F]fluorodeoxyglucose-positron emission tomography responses to vemurafenib in BRAF-mutant advanced melanoma
    • McArthur, G. A. et al. Marked, homogeneous, and early [18F]fluorodeoxyglucose-positron emission tomography responses to vemurafenib in BRAF-mutant advanced melanoma. J. Clin. Oncol. 30, 1628-1634 (2012).
    • (2012) J. Clin. Oncol , vol.30 , pp. 1628-1634
    • McArthur, G.A.1
  • 97
    • 79951818357 scopus 로고    scopus 로고
    • Apoptosis of human melanoma cells induced by inhibition of B-RAFV600E involves preferential splicing of bimS
    • Jiang, C. C. et al. Apoptosis of human melanoma cells induced by inhibition of B-RAFV600E involves preferential splicing of bimS. Cell Death Dis. 1, e69 (2010).
    • (2010) Cell Death Dis , vol.1
    • Jiang, C.C.1
  • 98
    • 84055212088 scopus 로고    scopus 로고
    • Targeted therapy for BRAFV600E malignant astrocytoma
    • Nicolaides, T. P. et al. Targeted therapy for BRAFV600E malignant astrocytoma. Clin. Cancer Res. 17, 7595-7604 (2011).
    • (2011) Clin. Cancer Res , vol.17 , pp. 7595-7604
    • Nicolaides, T.P.1
  • 99
    • 62849094740 scopus 로고    scopus 로고
    • Uncoupling of the LKB1-AMPKα energy sensor pathway by growth factors and oncogenic BRAFV600E
    • Esteve-Puig, R., Canals, F., Colome, N., Merlino, G. & Recio, J. A. Uncoupling of the LKB1-AMPKα energy sensor pathway by growth factors and oncogenic BRAFV600E. PLoS ONE 4, e4771 (2009).
    • (2009) PLoS ONE , vol.4
    • Esteve-Puig, R.1    Canals, F.2    Colome, N.3    Merlino, G.4    Recio, J.A.5
  • 100
    • 79956260998 scopus 로고    scopus 로고
    • Combination therapy with vemurafenib (PLX4032/RG7204) and metformin in melanoma cell lines with distinct driver mutations
    • Niehr, F. et al. Combination therapy with vemurafenib (PLX4032/RG7204) and metformin in melanoma cell lines with distinct driver mutations. J. Transl. Med. 9, 76 (2011).
    • (2011) J. Transl. Med , vol.9 , pp. 76
    • Niehr, F.1
  • 101
    • 79953064886 scopus 로고    scopus 로고
    • DHODH modulates transcriptional elongation in the neural crest and melanoma
    • White, R. M. et al. DHODH modulates transcriptional elongation in the neural crest and melanoma. Nature 471, 518-522 (2011).
    • (2011) Nature , vol.471 , pp. 518-522
    • White, R.M.1
  • 102
    • 79953325104 scopus 로고    scopus 로고
    • PTEN loss confers BRAF inhibitor resistance to melanoma cells through the suppression of BIM expression
    • Paraiso, K. H. et al. PTEN loss confers BRAF inhibitor resistance to melanoma cells through the suppression of BIM expression. Cancer Res. 71, 2750-2760 (2011).
    • (2011) Cancer Res , vol.71 , pp. 2750-2760
    • Paraiso, K.H.1
  • 103
    • 84863230465 scopus 로고    scopus 로고
    • Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR
    • Prahallad, A. et al. Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR. Nature 483, 100-103 (2012).
    • (2012) Nature , vol.483 , pp. 100-103
    • Prahallad, A.1
  • 104
    • 84861863158 scopus 로고    scopus 로고
    • EGFR-mediated reactivation of MAPK signaling contributes to insensitivity of BRAF-mutant colorectal cancers to RAF inhibition with vemurafenib
    • Corcoran, R. B. et al. EGFR-mediated reactivation of MAPK signaling contributes to insensitivity of BRAF-mutant colorectal cancers to RAF inhibition with vemurafenib. Cancer Discov. 2, 227-235 (2012).
    • (2012) Cancer Discov , vol.2 , pp. 227-235
    • Corcoran, R.B.1
  • 105
    • 49649118852 scopus 로고    scopus 로고
    • Elevated CRAF as a potential mechanism of acquired resistance to BRAF inhibition in melanoma
    • Montagut, C. et al. Elevated CRAF as a potential mechanism of acquired resistance to BRAF inhibition in melanoma. Cancer Res. 68, 4853-4861 (2008).
    • (2008) Cancer Res , vol.68 , pp. 4853-4861
    • Montagut, C.1
  • 106
    • 78650303507 scopus 로고    scopus 로고
    • Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation
    • Nazarian, R. et al. Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation. Nature 468, 973-977 (2010).
    • (2010) Nature , vol.468 , pp. 973-977
    • Nazarian, R.1
  • 107
    • 78650008177 scopus 로고    scopus 로고
    • Acquired resistance to BRAF inhibitors mediated by a RAF kinase switch in melanoma can be overcome by cotargeting MEK and IGF-1R/PI3K
    • Villanueva, J. et al. Acquired resistance to BRAF inhibitors mediated by a RAF kinase switch in melanoma can be overcome by cotargeting MEK and IGF-1R/PI3K. Cancer Cell 18, 683-695 (2010).
    • (2010) Cancer Cell , vol.18 , pp. 683-695
    • Villanueva, J.1
  • 108
    • 84859183431 scopus 로고    scopus 로고
    • Melanoma whole-exome sequencing identifies V600EB-RAF amplification-mediated acquired B-RAF inhibitor resistance
    • Shi, H. et al. Melanoma whole-exome sequencing identifies V600EB-RAF amplification-mediated acquired B-RAF inhibitor resistance. Nature Commun. 3, 724 (2012).
    • (2012) Nature Commun , vol.3 , pp. 724
    • Shi, H.1
  • 109
    • 79953240219 scopus 로고    scopus 로고
    • Amplification of the driving oncogene, KRAS or BRAF, underpins acquired resistance to MEK1/2 inhibitors in colorectal cancer cells
    • Little, A. S. et al. Amplification of the driving oncogene, KRAS or BRAF, underpins acquired resistance to MEK1/2 inhibitors in colorectal cancer cells. Sci. Signal. 4, ra17 (2011).
    • (2011) Sci. Signal , vol.4
    • Little, A.S.1
  • 110
    • 78649436372 scopus 로고    scopus 로고
    • BRAF gene amplification can promote acquired resistance to MEK inhibitors in cancer cells harboring the BRAF V600E mutation
    • Corcoran, R. B. et al. BRAF gene amplification can promote acquired resistance to MEK inhibitors in cancer cells harboring the BRAF V600E mutation. Sci. Signal. 3, ra84 (2010).
    • (2010) Sci. Signal , vol.3
    • Corcoran, R.B.1
  • 111
    • 84864285794 scopus 로고    scopus 로고
    • Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion
    • Straussman, R. et al. Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion. Nature 487, 500-504 (2012).
    • (2012) Nature , vol.487 , pp. 500-504
    • Straussman, R.1
  • 112
    • 84864286442 scopus 로고    scopus 로고
    • Widespread potential for growth-factor-driven resistance to anticancer kinase inhibitors
    • Wilson, T. R. et al. Widespread potential for growth-factor-driven resistance to anticancer kinase inhibitors. Nature 487, 505-509 (2012).
    • (2012) Nature , vol.487 , pp. 505-509
    • Wilson, T.R.1
  • 113
    • 79951961755 scopus 로고    scopus 로고
    • Resistance to BRAF inhibition in melanomas
    • Solit, D. B. & Rosen, N. Resistance to BRAF inhibition in melanomas. N. Engl. J. Med. 364, 772-774 (2011).
    • (2011) N. Engl. J. Med , vol.364 , pp. 772-774
    • Solit, D.B.1    Rosen, N.2
  • 114
    • 83455254767 scopus 로고    scopus 로고
    • RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E)
    • Poulikakos, P. I. et al. RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E). Nature 480, 387-390 (2011).
    • (2011) Nature , vol.480 , pp. 387-390
    • Poulikakos, P.I.1
  • 118
    • 75149117479 scopus 로고    scopus 로고
    • Impact of feedback phosphorylation and Raf heterodimerization on normal and mutant B-Raf signaling
    • Ritt, D. A., Monson, D. M., Specht, S. I. & Morrison, D. K. Impact of feedback phosphorylation and Raf heterodimerization on normal and mutant B-Raf signaling. Mol. Cell. Biol. 30, 806-819 (2010).
    • (2010) Mol. Cell. Biol , vol.30 , pp. 806-819
    • Ritt, D.A.1    Monson, D.M.2    Specht, S.I.3    Morrison, D.K.4
  • 119
    • 77949685981 scopus 로고    scopus 로고
    • RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth
    • Hatzivassiliou, G. et al. RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth. Nature 464, 431-435 (2010).
    • (2010) Nature , vol.464 , pp. 431-435
    • Hatzivassiliou, G.1
  • 120
    • 79955472800 scopus 로고    scopus 로고
    • A Raf-induced allosteric transition of KSR stimulates phosphorylation of MEK
    • Brennan, D. F. et al. A Raf-induced allosteric transition of KSR stimulates phosphorylation of MEK. Nature 472, 366-369 (2011).
    • (2011) Nature , vol.472 , pp. 366-369
    • Brennan, D.F.1
  • 121
    • 79953784580 scopus 로고    scopus 로고
    • RAF inhibitor-induced KSR1/B-RAF binding and its effects on ERK cascade signaling
    • McKay, M. M., Ritt, D. A. & Morrison, D. K. RAF inhibitor-induced KSR1/B-RAF binding and its effects on ERK cascade signaling. Curr. Biol. 21, 563-568 (2011).
    • (2011) Curr. Biol , vol.21 , pp. 563-568
    • McKay, M.M.1    Ritt, D.A.2    Morrison, D.K.3
  • 122
    • 79955044151 scopus 로고    scopus 로고
    • Mutation that blocks ATP binding creates a pseudokinase stabilizing the scaffolding function of kinase suppressor of Ras, CRAF and BRAF
    • Hu, J. et al. Mutation that blocks ATP binding creates a pseudokinase stabilizing the scaffolding function of kinase suppressor of Ras, CRAF and BRAF. Proc. Natl Acad. Sci. USA 108, 6067-6072 (2011).
    • (2011) Proc. Natl Acad. Sci. USA , vol.108 , pp. 6067-6072
    • Hu, J.1
  • 123
    • 84862908097 scopus 로고    scopus 로고
    • RAS mutations in cutaneous squamous-cell carcinomas in patients treated with BRAF inhibitors
    • Su, F. et al. RAS mutations in cutaneous squamous-cell carcinomas in patients treated with BRAF inhibitors. N. Engl. J. Med. 366, 207-215 (2012).
    • (2012) N. Engl. J. Med , vol.366 , pp. 207-215
    • Su, F.1
  • 124
    • 84862908526 scopus 로고    scopus 로고
    • RAS mutations are associated with the development of cutaneous squamous cell tumors in patients treated with RAF inhibitors
    • Oberholzer, P. A. et al. RAS mutations are associated with the development of cutaneous squamous cell tumors in patients treated with RAF inhibitors. J. Clin. Oncol. 30, 316-321 (2012).
    • (2012) J. Clin. Oncol , vol.30 , pp. 316-321
    • Oberholzer, P.A.1
  • 125
    • 84861417677 scopus 로고    scopus 로고
    • BRAF inhibition in refractory hairy-cell leukemia
    • Dietrich, S. et al. BRAF inhibition in refractory hairy-cell leukemia. N. Engl. J. Med. 366, 2038-2040 (2012).
    • (2012) N. Engl. J. Med , vol.366 , pp. 2038-2040
    • Dietrich, S.1
  • 126
    • 84866595717 scopus 로고    scopus 로고
    • A patient with BRAF V600E lung adenocarcinoma responding to vemurafenib
    • Gautschi, O. et al. A patient with BRAF V600E lung adenocarcinoma responding to vemurafenib. J. Thorac. Oncol. 7, e23-e24 (2012).
    • (2012) J. Thorac. Oncol , vol.7
    • Gautschi, O.1
  • 127
    • 78650391890 scopus 로고    scopus 로고
    • The oncogenic BRAF kinase inhibitor PLX4032/RG7204 does not affect the viability or function of human lymphocytes across a wide range of concentrations
    • Comin-Anduix, B. et al. The oncogenic BRAF kinase inhibitor PLX4032/RG7204 does not affect the viability or function of human lymphocytes across a wide range of concentrations. Clin. Cancer Res. 16, 6040-6048 (2010).
    • (2010) Clin. Cancer Res , vol.16 , pp. 6040-6048
    • Comin-Anduix, B.1
  • 128
    • 77954373338 scopus 로고    scopus 로고
    • Selective BRAFV600E inhibition enhances T-cell recognition of melanoma without affecting lymphocyte function
    • Boni, A. et al. Selective BRAFV600E inhibition enhances T-cell recognition of melanoma without affecting lymphocyte function. Cancer Res. 70, 5213-5219 (2010).
    • (2010) Cancer Res , vol.70 , pp. 5213-5219
    • Boni, A.1
  • 129
    • 4544367874 scopus 로고    scopus 로고
    • Technology platforms for pharmacogenomic diagnostic assays
    • DOI 10.1038/nrd1496
    • Koch, W. H. Technology platforms for pharmacogenomic diagnostic assays. Nature Rev. Drug Discov. 3, 749-761 (2004). (Pubitemid 39242827)
    • (2004) Nature Reviews Drug Discovery , vol.3 , Issue.9 , pp. 749-761
    • Koch, W.H.1
  • 130
    • 84857232726 scopus 로고    scopus 로고
    • Analytical performance of a real-time PCR-based assay for V600 mutations in the BRAF gene, used as the companion diagnostic test for the novel BRAF inhibitor vemurafenib in metastatic melanoma
    • Halait, H. et al. Analytical performance of a real-time PCR-based assay for V600 mutations in the BRAF gene, used as the companion diagnostic test for the novel BRAF inhibitor vemurafenib in metastatic melanoma. Diagn. Mol. Pathol. 21, 1-8 (2012).
    • (2012) Diagn. Mol. Pathol , vol.21 , pp. 1-8
    • Halait, H.1
  • 131
    • 72949090154 scopus 로고    scopus 로고
    • Cancer research. Melanoma drug vindicates targeted approach
    • Garber, K. Cancer research. Melanoma drug vindicates targeted approach. Science 326, 1619 (2009).
    • (2009) Science , vol.326 , pp. 1619
    • Garber, K.1
  • 132
    • 0026754369 scopus 로고
    • Activation of the MAP kinase pathway by the protein kinase raf
    • Howe, L. R. et al. Activation of the MAP kinase pathway by the protein kinase raf. Cell 71, 335-342 (1992).
    • (1992) Cell , vol.71 , pp. 335-342
    • Howe, L.R.1
  • 133
    • 0025355689 scopus 로고
    • Transactivation of c-fos and β-actin genes by raf as a step in early response to transmembrane signals
    • Jamal, S. & Ziff, E. Transactivation of c-fos and β-actin genes by raf as a step in early response to transmembrane signals. Nature 344, 463-466 (1990).
    • (1990) Nature , vol.344 , pp. 463-466
    • Jamal, S.1    Ziff, E.2
  • 134
    • 33947594129 scopus 로고    scopus 로고
    • Hyperactive Ras in developmental disorders and cancer
    • DOI 10.1038/nrc2109, PII NRC2109
    • Schubbert, S., Shannon, K. & Bollag, G. Hyperactive Ras in developmental disorders and cancer. Nature Rev. Cancer 7, 295-308 (2007). (Pubitemid 46480970)
    • (2007) Nature Reviews Cancer , vol.7 , Issue.4 , pp. 295-308
    • Schubbert, S.1    Shannon, K.2    Bollag, G.3
  • 135
    • 0027200883 scopus 로고
    • Direct interaction of Ras and the amino-terminal region of Raf-1 in vitro
    • DOI 10.1038/364352a0
    • Warne, P. H., Viciana, P. R. & Downward, J. Direct interaction of Ras and the amino-terminal region of Raf-1 in vitro. Nature 364, 352-355 (1993). (Pubitemid 23265279)
    • (1993) Nature , vol.364 , Issue.6435 , pp. 352-355
    • Warne, P.H.1    Viciana, P.R.2    Downward, J.3
  • 136
    • 0028272507 scopus 로고
    • Requirement for Ras in Raf activation is overcome by targeting Raf to the plasma membrane
    • DOI 10.1038/369411a0
    • Leevers, S. J., Paterson, H. F. & Marshall, C. J. Requirement for Ras in Raf activation is overcome by targeting Raf to the plasma membrane. Nature 369, 411-414 (1994). (Pubitemid 24184056)
    • (1994) Nature , vol.369 , Issue.6479 , pp. 411-414
    • Leevers, S.J.1    Paterson, H.F.2    Marshall, C.J.3
  • 137
    • 0029811985 scopus 로고    scopus 로고
    • Oligomerization activates c-Raf-1 through a Ras-dependent mechanism
    • DOI 10.1038/383181a0
    • Luo, Z. et al. Oligomerization activates c-Raf-1 through a Ras-dependent mechanism. Nature 383, 181-185 (1996). (Pubitemid 26303983)
    • (1996) Nature , vol.383 , Issue.6596 , pp. 181-185
    • Luo, Z.1    Tzivion, G.2    Belshaw, P.J.3    Vavvas, D.4    Marshall, M.5    Avruch, J.6
  • 138
    • 0035328521 scopus 로고    scopus 로고
    • Active ras induces heterodimerization of cRaf and BRaf
    • Weber, C. K., Slupsky, J. R., Kalmes, H. A. & Rapp, U. R. Active Ras induces heterodimerization of cRaf and BRaf. Cancer Res. 61, 3595-3598 (2001). (Pubitemid 32694968)
    • (2001) Cancer Research , vol.61 , Issue.9 , pp. 3595-3598
    • Weber, C.K.1    Slupsky, J.R.2    Andreas Kalmes, H.3    Rapp, U.R.4


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.